Cryoport, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $48.97 million, a 7.7% increase from $45.45 million in the same period last year. The growth was primarily driven by a 14.8% rise in Life Sciences Services revenue, which reached $27.97 million, up from $24.37 million. Life Sciences Products revenue, however, saw a slight decline of 0.4%, totaling $21.00 million compared to $21.09 million in the prior year. The company's gross margin improved to 46.6% from 47.0%, reflecting a total cost of revenue increase of 8.6% to $26.15 million.

In terms of profitability, Cryoport reported a net loss of $8.26 million for the quarter, a significant decrease from a net income of $108.87 million in the same quarter of 2025, which included a substantial gain from the sale of its CRYOPDP business. The loss attributable to common stockholders was $10.26 million, translating to a net loss per share of $0.20, compared to earnings of $2.13 per share in the previous year. The company’s operating expenses also increased, with selling, general, and administrative expenses rising by 4.1% to $28.01 million.

Operationally, Cryoport supported 779 clinical trials as of June 30, 2026, an increase from 728 trials a year earlier, with 94 of these in Phase 3. The company continues to expand its market share in the cell and gene therapy sector, which is expected to drive future revenue growth. The company’s strategic focus on enhancing its temperature-controlled supply chain solutions is evident, as it aims to support the growing demand in the life sciences sector.

Geographically, Cryoport's revenue from international customers accounted for approximately 24.7% of total revenue in the second quarter, with notable contributions from the EMEA and APAC regions. The company reported cash and cash equivalents of $269.27 million as of June 30, 2026, alongside short-term investments of $127.43 million, indicating a solid liquidity position. Looking ahead, Cryoport anticipates continued investment in its supply chain initiatives and technology to support growth, while also managing its operational costs and preparing for the repayment of its 2026 Convertible Senior Notes.

About Cryoport, Inc.

Cryoport Inc. provides global temperature-controlled supply chain solutions for the life sciences industry, specializing in supporting cell and gene therapies, biologics, and high-value biologic materials. Its offerings include logistics, cryopreservation, biostorage, cryogenic systems, and informatics platforms ensuring regulatory compliance, product integrity, and real-time monitoring. The company’s competitive edge lies in its integrated platform, advanced technology, and focus on de-risking critical biological material transportation and storage.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov